Below is the OCR text representation for this newspapers page.

STICKDOKU BY TERRY STICKELS Use your logic to find the correct number for each square. When finished, all nine rows across, all nine columns down and all nine 3-by-3 boxes must contain all nine numbers, 1 through 9, with no repeats. 1 7 1 8 1 1 6 1 I T 8 6 7_ _8 2 5 6_ 7_ 2 _1 9 7__3_ _2 1 6 i a 7 5 3 Difficulty level: Easy (Answers below) Print a larger version at usawcekendxom. GET USA WEEKEND'S JOKE OF THE DAYON YOUR CELLPHONE Simply send a text message to 44636 (4INFO) with the word JOKE in the body of your message. m Exclusively from USA WEEKEND! STICK l doku p: 1 M A ii——— m ■L_? .i - ■ ■j 8 ~■ 7 ' | IT~ •« 2 J ir~r~ 30 USA WEEKEND • Sept. 14-16,2007 Enjoy your favorite number brainteasers in book form. All new puzzles! Ordertoday! Only $4.95, plus shipping and handling Available ONLY at usaweekend.com FRAME GAMES BY TERRY STICKELS Can you solve these puzzles? Each communicates a well-known saying, person, place or thing. Answers below. O r:--.:: P S T B A F O P V U D A L O S V S I R I I H T T NCI IS E E O C S N S S 0 ! r o u R SETTLEMENT e GONE GONE GONE CONCLUSION GONE o SKETCH l |e|s|6|/|zj9|B[fr Z_ 9_ _B_ l_ _6_ _Z_ _6__B__£__9__S_ Z_ _L_ _B_ _fr_ Z_ 6_ _S_ 9_ 9_l 2 8 £ 9 Z 6 -Ll. —! £__L_LJL _B_ Z_ _S_ _Z_ _6_ _S_ J_ _9_ _^_6_J__3__9__£__B__Z__£_ ; SU3MSNV nxoaxDiis v ipi3 tr uojsnpuco auo6ajcy •£ luaiuanaas ynco-p-wo ‘Z suuin|o3 jadedsM3|\j ‘i : SH3MSNV S3WV9 3WVU3 Geriatric Use A total of 654 subjects m double-blind, placebo controlled. efficacy trials who received ROZEREM were at least 65 years of age; of these. 199 were 75 years of age or older No overall differences in safety or efficacy were observed between elderly and younger adult subjects. ADVERSE REACTIONS Overview The data described in this section reflect exposure to ROZEREM in 4251 subjects, including 346 exposed for 6 months or longer, and 473 subjects for one year. Adverse Reactions Resulting in Discontinuation of Treatment Six percent of the 3594 individual subjects exposed to ROZEREM in clinical studies discontinued treat ment owing to an adverse event compared with the 2% of the 1370 subjects receiving placebo. The most frequent advetse events teadng to decontmuation in subjects receiving ROZEREM were somnolence (0.8%), dizziness (0.5%). nausea (0.3%), fatigue (0.3%). headache (0.3%), and insomnia (0.3%). ROZEREM Most Commonly Observed Adverse Events in Phase 1-3 trials The incidence of adverse events during the Phase 1 through 3 trials!% placebo. n=1370; % rametteon [8 mg], n=1250) were: headache NOS (7%, 7%). somnolence (3%. 5%). fatigue (2%. 4%), dizziness (3%, 5%), nausea (2%, 3%), insomnia exacerbated (2%. 3%), upper respiratory tract infection NOS (2%. 3%). dianhea NOS (2%, 2%). myalgia (1%, 2%). depression (1%. 2%). dysgeusia (1%, 2%). arthralgia (1%, 2%). influenza (0.1%), blood cortisol decreased (0.1%). Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of other drugs, and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates DRUG ABUSE AND DEPENDENCE ROZEREM is not a controlled substance Human Data: See the CLINICAL TRIALS section, Studies Pertinent to Safety Concerns for Sleep- Promoting Agents, in the Complete Prescribing Information. Animal Data: Rametteon did not produce any signals from animal behavioral studies indicating that the drug produces rewarding effects. Monkeys did not self-administer rametteon and the drug did not induce a conditioned place preference in rats. There was no generalization between rametteon and midazolam. Rametteon did not affect rotorod performance, an indicator of disruption of motor function, and it did not potentiate the ability of diazepam to interfere with rotorod performance. Discontinuation of rametteon in animals or in humans after chronic administration did not produce withdrawal signs. Rametteon does not appear to produce physical dependence. OVERDOSAGE Signs and Symptoms No cases of ROZEREM overdose have been reported during clinical development ROZEREM was administered in single doses up to 160 mg in an abuse liability trial. No safety or tolerability concerns were seen Recommended Treatment General symptomatic and supportive measures should be used, along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate vital signs should be moni tored, and general supportive measures employed. Hemodialysis does not effectively reduce exposure to ROZEREM. Therefore, the use of dialysis in the treatment of overdosage is not appropriate. Poison Control Center As with the management of all overdosage, the possibility of multiple drug ingestion should tie considered. The physician may contact a poison control center for current information on the management of overdosage Rx only Manufactured by. Takeda Pharmaceutical Company Limited 540-8645 Osaka. JAPAN Manufactured in: Takeda Ireland Ltd. Kilruddery. County Wicklow. Republic of Ireland Marketed by Takeda Pharmaceuticals America. Inc. One Takeda Parkway Deerfield. IL 60015 ROZEREM™ is a trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Pharmaceuticals America, Inc. 02005. Takeda Pharmaceuticals America. Inc. 05-1124 Revised: Apr. 2006 L-RAM-00035 FRAME GAAAfS BY TERRY STICKELS " TERRYSTICWISCOM